New gene therapy trial aims to turn immune system against cancer
NCT ID NCT06391918
Summary
This early-stage study is testing a new gene therapy called GEN2 in adults with advanced solid tumors that have stopped responding to standard treatments. The therapy aims to activate the patient's own immune system to recognize and attack their cancer. Researchers will test different doses given by IV or injection into a tumor to find the safest and most effective amount.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
UCLA Hematology-Oncology
Los Angeles, California, 90095, United States
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
-
University of Southern California-Keck School of Medicine
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.